Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1187-1192
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1187
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1187
Table 3 Patients’ characteristics at the time of infliximab treatment: the differential response to infliximab therapy in CD patients depends on their 5q31 genotype.
| Responder (n = 25) | Non-responder (n = 15) | P | |
| Demographics | |||
| Mean age, yr (range) | 35 (21-66) | 40 (17-68) | 0.21 |
| Mean duration of disease, yr (range) | 10 (1-27) | 12 (1-31) | 0.37 |
| Male:Female | 13:12 | 6:09 | 0.46 |
| Smoker, n (%) | 13 (52) | 8 (53.3) | 0.93 |
| Extraintestinal | 13 (52) | 7 (46) | 0.92 |
| manifestations, n (%) | |||
| Previous surgery, n (%) | 14 (56) | 9 (60) | 0.8 |
| Disease distribution | |||
| Small bowel only, n (%) | 9 (36) | 4 (26.7) | 0.54 |
| Colon only, n (%) | 3 (12) | 2 (13.3) | 1 |
| Colon and small bowel, n (%) | 13 (52) | 9 (66) | 0.62 |
| Indication for infliximab | |||
| Inflammatory disease only, n (%) | 7 (28) | 6 (40) | 0.62 |
| Fistulizing disease only, n (%) | 10 (40) | 7 (46.7) | 1 |
| Inflammatory and | 8 (32) | 2 (13.3) | 0.27 |
| fistulizing disease, n (%) | |||
| Concomitant medication | |||
| 6-mercaptopurine, azathioprine, | 17 (68) | 13 (86.7) | 0.27 |
| methotrexate, n (%) | |||
| Mesalamine, n (%) | 7 (28) | 4 (26.7) | 0.52 |
| Corticosteroid, n (%) | 6 (24) | 5 (33.3) | 1 |
| 5q31 genotype | |||
| Homozygous wild type, n (%) | 6 (24) | 3 (20) | 1 |
| Heterozygous, n (%) | 16 (64) | 5 (33.3) | 0.1 |
| Homozygous mutant, n (%) | 3 (12) | 7 (46.7) | 0.024a |
- Citation: Urcelay E, Mendoza JL, Martínez A, Fernández L, Taxonera C, Díaz-Rubio M, de la Concha EG. IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab. World J Gastroenterol 2005; 11(8): 1187-1192
- URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1187.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1187